1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. KWALITY PHARMACEUTICALS LTD.
Kwality Pharmaceuticals Ltd.
BSE: 539997

Kwality Pharma Live Share Price Today, Share Analysis and Chart

Strong Performer, Getting Expensive
aboutKwality Pharmaceuticals Ltd. is a research-driven pharmaceutical company specializing in the development and manufacturing of a diverse range of finished dosage formulations. The company maintains a significant presence in both domestic and internati... Read More
US FDA InspectionsANDA Approvals
Ask AI about Kwality Pharma
3824.45-117.75(-2.99%)

New 52W High in past week

101.9K
NSE+BSE Volume

High vol. this week

BSE 13 Nov, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Durability score
00 / 100
Valuation Score
00 / 100
Momentum Score
00 / 100
Analyst Price Target
No estimates available

34

S

7

W

0

O

1

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

17Positive6Negative

Pass in checklist73.9%

045
55
100

Check P/E Buy Sell Zone

Strong Sell Zone

88.0 %    into P/E buy sell zone

% time spent below current P/E
020406080100
Strong upside potential
Gains already realized

Kwality Pharma Stock Price Analysis

Day Price Range

-3.0% 1 Day return
3824.4 (LTP)
3,8004,096.2
LowHigh

Week Price Range

4.9% 1 Week return
3824.4 (LTP)
3,595.24,219.8
LowHigh

Month Price Range

8.3% 1 Month return
3824.4 (LTP)
3,2274,219.8
LowHigh

52 Week Price Range

293.7% 1 Year return
3824.4 (LTP)
8524,219.8
LowHigh
View full Price History/Seasonality

Kwality Pharma Technical Analysis

Kwality Pharma EMA & SMA

Bullish+6
7 bullish, 1 bearish
Bullish7
Bearish1
5 Day3846.2
10 Day3778.8
12 Day3757.0
20 Day3695.7
26 Day3663.2
50 Day3535.5
100 Day3211.8
200 Day2658.0

Kwality Pharma Delivery And Volume

Daily Avg. Delivery Volume %
13 Nov, 202637.9%
Week32.6%
Month39.0%

Kwality Pharma Active Candlesticks

Inside Uptrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Kwality Pharma Resistance and Support

3906.88
Pivot
First Resistance4013.8
Second Resistance4203.1
Third Resistance4310.0
First Support3717.6
Second Support3610.7
Third Support3421.4
Day RSI57
Day MACD93.8
Day MFI81.2
Day MACD Signal Line63.4

Kwality Pharma Beta

1 Month-0.2
1 Year0.7
3 Month0.6
3 Year0.7

Kwality Pharma Price Change Analysis

↑8.3%
Over 1 Month
LowHigh
32274219.8
↑14.9%
Over 3 Months
LowHigh
3132.84219.8
↑127.9%
Over 6 Months
LowHigh
16514219.8
↑293.7%
Over 1 Year
LowHigh
852.04219.8
All Technicals →

Kwality Pharma Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Ramesh AroraPromoter2,700,63226.0 %
Ark Global Emerging Companies, LpFii190,5181.8 %
Deepak BansalPublic846,5258.2 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Kwality Pharma Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
ARK GLOBAL EMERGING COMPANIES, LPBulkPurchase09 Jan 20261130.0476,400BSE
DEEPAK BANSALBulkSell09 Jan 20261122.4269,353BSE
AKNM SUPPLIERS PRIVATE LIMITEDBulkSell10 Jul 2023316.41137,152BSE
AKNM SUPPLIERS PRIVATE LIMITEDBulkSell03 Jul 2023295.10150,000BSE
BLUEPEAK CONSULTANCY LLPBulkPurchase03 Jul 202329575,000BSE
AKNM SUPPLIERS PRIVATE LIMITEDBulkSell30 Jun 2023295.38104,000BSE
AKNM SUPPLIERS PRIVATE LIMITEDBulkSell26 Jun 2023294.07158,564BSE
AKNM SUPPLIERS PRIVATE LIMITEDBulkSell08 Jun 2023295.49100,000BSE
AKNM SUPPLIERS PRIVATE LIMITEDBulkSell05 Jun 2023295.19100,000BSE
AKNM SUPPLIERS PRIVATE LIMITEDBulkSell19 Jan 2023344.24250,000BSE
All deals
All insider trades

Kwality Pharma Corporate Actions

Kwality Pharma Dividend history and yield

Kwality Pharma dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Kwality Pharma dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
105 Jan 2017
0.6INTERIM06 Jan 2017Equity Share

Kwality Pharma Bonus shares

Kwality Pharma bonus history along with announcement, record, ex-bonus dates, and bonus ratios.

#Ex-Date
Bonus RatioRecord Date
111 Oct 2017
1:112 Oct 2017

Kwality Pharma Board Meetings

Kwality Pharma past and upcoming board meetings.

#Ex-Date
PurposeNotes
112 Nov 2026
Quarterly Results-
210 Aug 2026
Quarterly Results-
319 May 2026
Audited Results-
412 Feb 2026
Quarterly Results-
513 Nov 2025
Quarterly Results-
All Corporate Actions

Kwality Pharma Corporate Filings

Kwality Pharma BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
14 Nov 2026
Kwality Pharmaceuticals Ltd - 539997 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Recording of Investor/ Analyst Earnings Call held on November 13, 2026
PDF
14 Nov 2026
Kwality Pharmaceuticals Ltd - 539997 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Intimation under Regulation 30 of the SEBI(LODR), 2015 -Recording of Investor/ Analyst Earnings Call held on September 13, 2026
PDF
12 Nov 2026
Q2FY27 Quarterly Result Announced for Kwality Pharmaceuticals Ltd.
Pharmaceuticals company Kwality Pharmaceuticals announced Q2FY27 results Consolidated Financial Highlights: Revenue from Operations: For Q2FY27, revenue from operations stood at Rs 18,122.29 lakh, up 11.62% QoQ from Rs 16,235.22 lakh in Q1FY27 and up 63.19% YoY from Rs 11,105.10 lakh in Q2FY26. For H1FY27, revenue from operations reached Rs 34,357.51 lakh, rising 54.40% YoY from Rs 22,253.00 lakh in H1FY26. Total Income: For Q2FY27, total revenue stood at Rs 18,199.38 lakh, increasing 11.67% QoQ from Rs 16,297.49 lakh in Q1FY27 and 62.57% YoY from Rs 11,194.82 lakh in Q2FY26. For H1FY27, total revenue was Rs 34,496.86 lakh, growing 54.14% YoY from Rs 22,380.29 lakh in H1FY26. Profit Before Tax (PBT): For Q2FY27, PBT stood at Rs 4,221.77 lakh, up 24.22% QoQ from Rs 3,398.70 lakh in Q1FY27 and up 128.82% YoY from Rs 1,845.05 lakh in Q2FY26. For H1FY27, PBT reached Rs 7,620.48 lakh, surging 114.79% YoY from Rs 3,547.84 lakh in H1FY26. Profit After Tax (PAT): For Q2FY27, PAT stood at Rs 2,902.62 lakh, growing 13.28% QoQ from Rs 2,562.23 lakh in Q1FY27 and 105.63% YoY from Rs 1,411.57 lakh in Q2FY26. For H1FY27, PAT reached Rs 5,464.85 lakh, up 109.90% YoY from Rs 2,603.55 lakh in H1FY26. Earnings Per Share (EPS): For Q2FY27, basic and diluted EPS stood at Rs 27.93, rising 13.12% QoQ from Rs 24.69 in Q1FY27 and 105.37% YoY from Rs 13.60 in Q2FY26. For H1FY27, basic and diluted EPS stood at Rs 52.63, up 109.76% YoY from Rs 25.09 in H1FY26. Standalone Financial Highlights: Revenue from Operations: For Q2FY27, revenue from operations stood at Rs 18,116.79 lakh, up 11.59% QoQ from Rs 16,235.22 lakh in Q1FY27 and up 62.76% YoY from Rs 11,131.31 lakh in Q2FY26. For H1FY27, revenue from operations reached Rs 34,352.01 lakh, growing 54.19% YoY from Rs 22,279.20 lakh in H1FY26. Total Income: For Q2FY27, total revenue stood at Rs 18,193.88 lakh, increasing 11.64% QoQ from Rs 16,297.49 lakh in Q1FY27 and 62.14% YoY from Rs 11,221.03 lakh in Q2FY26. For H1FY27, total revenue was Rs 34,491.37 lakh, up 53.93% YoY from Rs 22,406.50 lakh in H1FY26. Profit Before Tax (PBT): For Q2FY27, PBT stood at Rs 4,221.58 lakh, rising 24.20% QoQ from Rs 3,399.15 lakh in Q1FY27 and 128.80% YoY from Rs 1,845.12 lakh in Q2FY26. For H1FY27, PBT reached Rs 7,620.73 lakh, up 114.72% YoY from Rs 3,549.15 lakh in H1FY26. Profit After Tax (PAT): For Q2FY27, PAT stood at Rs 2,902.42 lakh, increasing 13.26% QoQ from Rs 2,562.68 lakh in Q1FY27 and 105.61% YoY from Rs 1,411.64 lakh in Q2FY26. For H1FY27, PAT reached Rs 5,465.10 lakh, growing 109.80% YoY from Rs 2,604.86 lakh in H1FY26. Earnings Per Share (EPS): For Q2FY27, basic and diluted EPS stood at Rs 27.97, up 13.24% QoQ from Rs 24.70 in Q1FY27 and up 105.66% YoY from Rs 13.60 in Q2FY26. For H1FY27, basic and diluted EPS stood at Rs 52.67, rising 109.84% YoY from Rs 25.10 in H1FY26. Result PDF
PDF
12 Nov 2026
Kwality Pharmaceuticals Ltd - 539997 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the quarter and half year ended unaudited financial results for 30-09-2026
PDF
12 Nov 2026
Kwality Pharmaceuticals Ltd - 539997 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
Appointment of new Statutory Auditors
PDF
VIEW ALL

Kwality Pharma Documents

Kwality Pharma Earnings Call

Kwality Pharma earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
12 Aug 2026Kwality Pharmaceuticals Ltd - 539997 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptPdf
12 Aug 2026Kwality Pharmaceuticals Ltd - 539997 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptPdf
21 May 2026Kwality Pharmaceuticals Ltd - 539997 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptPdf
view all

Kwality Pharma Annual Reports

Kwality Pharma financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Pdf
2025Annual Report Mar-2025Pdf
2024Annual Report Mar-2024Pdf
2023Annual Report Mar-2023Pdf
2022Annual Report Mar-2022Pdf

Kwality Pharma Credit Ratings

Kwality Pharma credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
05 Nov 2026crisil ratingsKwality Pharmaceuticals LimitedKwality Pharmaceuticals Limited:Issuer not cooperating, based on best-available information; Ratings revised to 'Crisil BB-/Stable/Crisil A4+ Issuer not cooperating\u2019Link
05 Oct 2026care ratingsKPL International LimitedPdf
06 May 2026icra ratingsKwality Pharmaceuticals Ltd.Ratings upgraded to [ICRA]BBB+ (Stable)/[ICRA]A2; rated amount enhanced; removed from Issuer Not Cooperating categoryLink
04 Dec 2025icra ratingsKwality Pharmaceuticals Ltd.Continues to remain under issuer non-cooperating categoryLink
24 Sep 2025crisil ratingsKwality Pharmaceuticals LimitedKwality Pharmaceuticals Limited:Issuer not cooperating, based on best-available information; Ratings continues to be \u2018Crisil B/Stable/Crisil A4 Issuer not cooperating\u2019Link

Kwality Pharma Investor Presentations

Kwality Pharma investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
12 Nov 2026Kwality Pharmaceuticals Ltd - 539997 - Announcement under Regulation 30 (LODR)-Investor PresentationPdf
10 Aug 2026Kwality Pharmaceuticals Ltd - 539997 - Announcement under Regulation 30 (LODR)-Investor PresentationPdf
19 May 2026Kwality Pharmaceuticals Ltd - 539997 - Announcement under Regulation 30 (LODR)-Investor PresentationPdf
12 Feb 2026Kwality Pharmaceuticals Ltd - 539997 - Investor Presentation Of Financial Results For The Quarter And Nine Months Ended December 31, 2025Pdf
05 Jun 2025Kwality Pharmaceuticals Ltd - 539997 - Announcement under Regulation 30 (LODR)-Investor PresentationPdf

Kwality Pharma - Company Profile

Kwality Pharma Management Structure

Kwality Pharma management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Aditya AroraExecutive Director,Whole Time Director,Chief Financial Officer54Mar 26
Mr. Narinder JassalHead(QC)-Mar 26
Mr. Sudhansu Sekliar RautarayHead(Plant)-Mar 26
Mr. Harshvardhan GuptaManager(QA)-Mar 26
Mr. Akhilesh Kumar BindHead(QC)-Mar 26
Mr. Mukesh OjhaHead(R & D)-Mar 26
Gurpreet KaurCompany Secretary,Compliance Officer-Mar 26
Mr. Sandeep Raghuvir NaikHead(Plant)-Mar 26

Kwality Pharma Board of Directors

Kwality Pharma Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Ajay AroraE D & Wholetime Director84Mar 26
Ramesh KumarExecutive Director & MD84Mar 26
Aditya AroraExecutive Director / Whole Time Director / CFO54Mar 26
Anju AroraE D & Wholetime Director36Mar 26
Geeta AroraE D & Wholetime Director36Mar 26
Vinod Kumar SharmaIndependent Non Exe. Director3Mar 26
PreetMohinder Singh BediIndependent Non Exe. Director1Mar 26
Bhavesh MahajanIndependent Non Exe. Director0.3Mar 26
Prashanth VellankiIndependent Non Exe. Director0.1Mar 26
Gurpreet KaurCompany Sec. & Compli. Officer-Mar 26
Swanith KapoorIndependent Non Exe. Director-Mar 26
Website: www.kwalitypharma.com

About the company - Business Profile

Kwality Pharmaceuticals Ltd. is a research-driven pharmaceutical company specializing in the development and manufacturing of a diverse range of finished dosage formulations. The company maintains a significant presence in both domestic and international markets, with operations spanning over 70 countries across regions including the Middle East, French West Africa, Latin America (LATAM), and South East Asia (ASEAN).

Key Points

  • Key Facts: Founded in 1983 and headquartered in Amritsar, Punjab, the company is listed on the Bombay Stock Exchange (BSE). Its product portfolio includes over 3,000 formulations across 25+ therapeutic segments.
  • Operations and Resources: The company operates five manufacturing facilities located in Punjab and Himachal Pradesh. These units possess capabilities for both Oral Solid Dosages (OSD) and injectables, including specialized lines for Oncology, Cephalosporins, Beta Lactams, and Hormones.
  • Market and Significance: KPL is a key player in the global generics market, particularly in complex and niche injectables. It serves regulated and semi-regulated markets with approvals from global agencies including PIC/S (ANVISA, SFDA), INVIMA (Colombia), DIGEMID (Peru), and EU-GMP.
  • Business Model: KPL operates an integrated pharmaceutical model focusing on R&D, manufacturing, and global distribution. It excels in navigating complex regulatory environments to secure product registrations in diverse geographies and maintains long-standing partnerships with multinational pharmaceutical companies and distributors.
  • Financial Performance (FY25):
    • Consolidated Revenue: ₹372.12 crore (compared to ₹309.00 crore in FY24).
    • Profit After Tax (PAT): ₹39.80 crore (compared to ₹23.62 crore in FY24).
    • Revenue Growth: Achieved a CAGR of approximately 22% from FY23 to FY25.
    • Segment Reporting: The company operates primarily in a single reportable segment: Pharmaceuticals.
  • Key Products and Technology:
    • Advanced Formulations: Focus on complex products such as Microspheres, Liposomes, and Nanoparticles.
    • Biologics and Peptides: Established a dedicated Biological Unit; developed proof of concept for its first biosimilar, Erythropoietin. Ongoing development for Etanercept and Alteplase.
    • Recent Approvals: Secured SFDA approval for General and Beta Lactam units and successfully completed EU-GMP audits for these units in FY25.
  • Human Resources: The company employs over 1,700 personnel, including a dedicated R&D team of more than 80 scientists.
  • Subsidiaries: Includes Kwality Pharmaceuticals Africa, Limitada (51% ownership).
  • Strategic Initiatives and Outlook:
    • FY26 Targets: Management has set a consolidated revenue target of ₹500 crore with projected EBITDA margins between 22% and 25%.
    • Capacity Expansion: Ongoing construction of Unit-6 and expansion in biologics and oncology capacities.
    • Long-term Goals: Targets revenue of ₹1,000–₹1,100 crore by FY29, driven by a projected 30% CAGR and expanded market access in regulated regions.

Kwality Pharma FAQ

Kwality Pharma today is trading in the red, down by 2.99% at ₹3,824.45.
Kwality Pharma is currently trading down 2.99% on an intraday basis. In the past week the stock rose 4.92%. Stock has been up 14.94% in the past quarter and rose 293.7% in the past year. You can view this in the share price history/seasonality section.
Kwality Pharma is listed on NSE with the ticker KPL and on BSE as 539997. It's currently trading on NSE at a share price of ₹3,824.45 and on BSE with a share price of ₹3,822.6.
The market cap of Kwality Pharma is ₹3,968.33 Cr. as of Nov 13, 2026.
Kwality Pharma announced a INTERIM dividend of 6% which equals ₹0.6 in Jan 05, 2017.To view the full dividend history of Kwality Pharma click here.
Kwality Pharma has never issued stock splits, but it has issued 1 bonus shares since its BSE/NSE listing. The latest announcement for Kwality Pharma bonus shares was on Oct 11, 2017 at a ratio of 1:1.
Kwality Pharma reported ₹181.99 Cr. in revenue, ₹29.03 Cr. in net profit, and ₹50.57 Cr. in EBITD as of Nov 12, 2026 for Q2 FY26-27.
There are no analyst predictions for stock price target for Kwality Pharma.
The PE ratio of Kwality Pharma is 41.35 as of Nov 13, 2026.
The PB ratio of Kwality Pharma is 11.11 as of Nov 13, 2026.
There are no analyst reports for Kwality Pharma.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×